Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- Christine Mauz-Körholz
- Target Recruit Count
- 648
- Registration Number
- NCT00416832
Combination Chemotherapy and Surgery With or Without Radiation Therapy in Treating Patients With Stage 2 or Stage 3 Neuroblastoma
- Conditions
- Neuroblastoma
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 30
- Registration Number
- NCT00416676
Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant
- Conditions
- Neuroblastoma
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Registration Number
- NCT00417053
Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2016-09-26
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 83
- Registration Number
- NCT00416910
Clinical Trial of Mycophenolate Versus Cyclophosphamide in ANCA Vasculitis
- First Posted Date
- 2006-12-21
- Last Posted Date
- 2013-12-06
- Target Recruit Count
- 140
- Registration Number
- NCT00414128
- Locations
- 🇬🇧
Addenbrookes Hospital, Cambridge, Cambridgeshire, United Kingdom
VELCADE,Rituximab,Cyclophosphamide and Decadron
- Conditions
- Lymphoma, B-CellLymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2006-12-20
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- Oncology Specialists, S.C.
- Target Recruit Count
- 12
- Registration Number
- NCT00413959
- Locations
- 🇺🇸
Onocology Specialists, S.C, Niles, Illinois, United States
🇺🇸Oncology Specialists, S.C, Park Ridge, Illinois, United States
Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients
- Conditions
- Burkitt's LymphomaLymphoblastic LymphomaAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2013-03-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT00412243
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)
- Conditions
- Acute Lymphocytic LeukemiaChronic Myelogenous LeukemiaNatural Killer Cell Lymphoblastic Leukemia/LymphomaMyelodysplastic SyndromeAcute Myelogenous Leukemia
- Interventions
- Biological: Single Umbilical Cord Blood Unit TransplantBiological: Double Umbilical Cord Blood Unit TransplantRadiation: Total Body IrradiationDrug: CyclophosphamideDrug: FludarabineDrug: Cyclosporine ADrug: Mycophenolate Mofetil
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 224
- Registration Number
- NCT00412360
- Locations
- 🇺🇸
University of Mississippi, Jackson, Mississippi, United States
🇺🇸Children's Medical Center of Dallas, Dallas, Texas, United States
🇺🇸New York Medical College, Valhalla, New York, United States
Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma
- Conditions
- Neuroblastoma
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- German Society for Pediatric Oncology and Hematology GPOH gGmbH
- Target Recruit Count
- 642
- Registration Number
- NCT00410631
- Locations
- 🇩🇪
Kinderklinik - Universitaetsklinikum Aachen, Aachen, Germany
🇩🇪Klinikum Dortmund, Dortmund, Germany
🇩🇪Kliniken der Stadt Koeln gGmbH - Kinderkrankenhaus Riehl, Cologne, Germany
Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients
- Conditions
- Leukaemia, Lymphocytic, Chronic
- Interventions
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 61
- Registration Number
- NCT00410163
- Locations
- 🇬🇧
GSK Investigational Site, Plymouth, Devon, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.